- Home
- ITRM vs RNXT Comparison
ITRM vs RNXT Comparison
Compare ITRM & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- RNXT
- Stock Information
- Founded
- ITRM 2015
- RNXT 2012
- Country
- ITRM Ireland
- RNXT United States
- Employees
- ITRM N/A
- RNXT N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- ITRM Health Care
- RNXT Health Care
- Exchange
- ITRM Nasdaq
- RNXT Nasdaq
- Market Cap
- ITRM 40.0M
- RNXT 44.6M
- IPO Year
- ITRM 2018
- RNXT 2021
- Fundamental
- Price
- ITRM $0.68
- RNXT $1.28
- Analyst Decision
- ITRM Strong Buy
- RNXT Strong Buy
- Analyst Count
- ITRM 2
- RNXT 2
- Target Price
- ITRM $7.00
- RNXT $7.50
- AVG Volume (30 Days)
- ITRM 749.8K
- RNXT 594.5K
- Earning Date
- ITRM 11-13-2025
- RNXT 11-12-2025
- Dividend Yield
- ITRM N/A
- RNXT N/A
- EPS Growth
- ITRM N/A
- RNXT N/A
- EPS
- ITRM N/A
- RNXT N/A
- Revenue
- ITRM N/A
- RNXT $662,000.00
- Revenue This Year
- ITRM N/A
- RNXT $2,988.37
- Revenue Next Year
- ITRM $249.35
- RNXT $300.60
- P/E Ratio
- ITRM N/A
- RNXT N/A
- Revenue Growth
- ITRM N/A
- RNXT N/A
- 52 Week Low
- ITRM $0.61
- RNXT $0.75
- 52 Week High
- ITRM $3.02
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- ITRM 43.17
- RNXT 61.50
- Support Level
- ITRM $0.61
- RNXT $1.06
- Resistance Level
- ITRM $0.76
- RNXT $1.27
- Average True Range (ATR)
- ITRM 0.05
- RNXT 0.10
- MACD
- ITRM 0.01
- RNXT 0.04
- Stochastic Oscillator
- ITRM 49.65
- RNXT 69.64
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.